Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105


Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.

Jankowski W, Park Y, McGill J, Maraskovsky E, Hofmann M, Diego VP, Luu BW, Howard TE, Kellerman R, Key NS, Sauna ZE.

Blood Adv. 2019 May 14;3(9):1429-1440. doi: 10.1182/bloodadvances.2018030452.


A Novel Cellular Pathway of Antigen Presentation and CD4 T Cell Activation in vivo.

Scales HE, Meehan GR, Hayes AJ, Benson RA, Watson E, Walters A, Tomura M, Maraskovsky E, Garside P, Baz Morelli A, Brewer JM.

Front Immunol. 2018 Nov 22;9:2684. doi: 10.3389/fimmu.2018.02684. eCollection 2018.


A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.

Davis ID, Quirk J, Morris L, Seddon L, Tai TY, Whitty G, Cavicchiolo T, Ebert L, Jackson H, Browning J, MacGregor D, Wittke F, Winkels G, Alex R, Miloradovic L, Maraskovsky E, Chen W, Cebon J.

Immunotherapy. 2017 Mar;9(3):249-259. doi: 10.2217/imt-2016-0132. Epub 2017 Feb 10.


A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus.

Oon S, Huynh H, Tai TY, Ng M, Monaghan K, Biondo M, Vairo G, Maraskovsky E, Nash AD, Wicks IP, Wilson NJ.

JCI Insight. 2016 May 5;1(6):e86131. doi: 10.1172/jci.insight.86131.


G-CSF and Neutrophils Are Nonredundant Mediators of Murine Experimental Autoimmune Uveoretinitis.

Goldberg GL, Cornish AL, Murphy J, Pang ES, Lim LL, Campbell IK, Scalzo-Inguanti K, Chen X, McMenamin PG, Maraskovsky E, McKenzie BS, Wicks IP.

Am J Pathol. 2016 Jan;186(1):172-84. doi: 10.1016/j.ajpath.2015.09.008.


Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma.

Klein O, Davis ID, McArthur GA, Chen L, Haydon A, Parente P, Dimopoulos N, Jackson H, Xiao K, Maraskovsky E, Hopkins W, Stan R, Chen W, Cebon J.

Cancer Immunol Immunother. 2015 Apr;64(4):507-18. doi: 10.1007/s00262-015-1656-x. Epub 2015 Feb 7.


The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.

Silva A, Mount A, Krstevska K, Pejoski D, Hardy MP, Owczarek C, Scotney P, Maraskovsky E, Baz Morelli A.

J Immunol. 2015 Mar 1;194(5):2199-207. doi: 10.4049/jimmunol.1402228. Epub 2015 Feb 2.


Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling.

Robson NC, Hidalgo L, Mc Alpine T, Wei H, Martínez VG, Entrena A, Melen GJ, MacDonald AS, Phythian-Adams A, Sacedón R, Maraskovsky E, Cebon J, Ramírez M, Vicente A, Varas A.

Cancer Res. 2014 Sep 15;74(18):5019-5031. doi: 10.1158/0008-5472.CAN-13-2845. Epub 2014 Jul 18.


Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere trivalent influenza vaccine is associated with adverse events.

Rockman S, Dyson A, Koernig S, Becher D, Ng M, Morelli AB, Barnden M, Tang ML, Pearse M, Maraskovsky E.

Vaccine. 2014 Jun 24;32(30):3861-8. doi: 10.1016/j.vaccine.2014.03.032.


Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Campbell IK, Miescher S, Branch DR, Mott PJ, Lazarus AH, Han D, Maraskovsky E, Zuercher AW, Neschadim A, Leontyev D, McKenzie BS, Käsermann F.

J Immunol. 2014 Jun 1;192(11):5031-8. doi: 10.4049/jimmunol.1301611. Epub 2014 Apr 23.


Role of viral RNA and lipid in the adverse events associated with the 2010 Southern Hemisphere trivalent influenza vaccine.

Rockman S, Becher D, Dyson A, Koernig S, Morelli AB, Barnden M, Camuglia S, Soupourmas P, Pearse M, Maraskovsky E.

Vaccine. 2014 Jun 24;32(30):3869-76. doi: 10.1016/j.vaccine.2014.03.035. Epub 2014 Mar 25.


Inflammasome-dependent and -independent IL-18 production mediates immunity to the ISCOMATRIX adjuvant.

Wilson NS, Duewell P, Yang B, Li Y, Marsters S, Koernig S, Latz E, Maraskovsky E, Morelli AB, Schnurr M, Ashkenazi A.

J Immunol. 2014 Apr 1;192(7):3259-68. doi: 10.4049/jimmunol.1302011. Epub 2014 Mar 7.


Ex vivo restimulation of human PBMC expands a CD3+CD4-CD8- γδ+ T cell population that can confound the evaluation of CD4 and CD8 T cell responses to vaccination.

Sedgmen BJ, Papalia L, Wang L, Dyson AR, McCallum HA, Simson CM, Pearse MJ, Maraskovsky E, Hung D, Eomois PP, Hartel G, Barnden MJ, Rockman SP.

Clin Dev Immunol. 2013;2013:186420. doi: 10.1155/2013/186420. Epub 2013 Aug 26.


Response to letter by Paul Effler and Heath Kelly to vaccine.

Maraskovsky E.

Vaccine. 2013 Dec 17;32(1):2-3. doi: 10.1016/j.vaccine.2013.08.094. Epub 2013 Sep 12. No abstract available.


Combination of adjuvants: the future of vaccine design.

Mount A, Koernig S, Silva A, Drane D, Maraskovsky E, Morelli AB.

Expert Rev Vaccines. 2013 Jul;12(7):733-46. doi: 10.1586/14760584.2013.811185. Review.


New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.

Poland GA, Fleming DM, Treanor JJ, Maraskovsky E, Luke TC, Ball EM, Poland CM.

Vaccine. 2013 Apr 17;31 Suppl 1:A1-20. doi: 10.1016/j.vaccine.2013.02.033.


Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J, Behren A, Davis ID, Maraskovsky E, Chen W, Cebon J.

Eur J Immunol. 2013 Feb;43(2):533-9. doi: 10.1002/eji.201242603. Epub 2012 Dec 5.


Scientific investigations into febrile reactions observed in the paediatric population following vaccination with a 2010 Southern Hemisphere Trivalent Influenza Vaccine.

Maraskovsky E, Rockman S, Dyson A, Koernig S, Becher D, Morelli AB, Barnden M, Camuglia S, Bodle J, Vandenberg K, Wang IM, Cristescu R, Loboda A, Citron M, Fontenot J, Hung D, Schoofs P, Pearse M.

Vaccine. 2012 Dec 7;30(51):7400-6. doi: 10.1016/j.vaccine.2012.09.083. Epub 2012 Oct 9.


A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

Zhao RY, Mifsud NA, Xiao K, Chan KF, Oveissi S, Jackson HM, Dimopoulos N, Guillaume P, Knights AJ, Lowen T, Robson NC, Russell SE, Scotet E, Davis ID, Maraskovsky E, Cebon J, Luescher IF, Chen W.

PLoS One. 2012;7(9):e44707. doi: 10.1371/journal.pone.0044707. Epub 2012 Sep 6.


Targeting Dendritic Cells in vivo for Cancer Therapy.

Caminschi I, Maraskovsky E, Heath WR.

Front Immunol. 2012 Feb 7;3:13. doi: 10.3389/fimmu.2012.00013. eCollection 2012.


ISCOMATRIX: a novel adjuvant for use in prophylactic and therapeutic vaccines against infectious diseases.

Morelli AB, Becher D, Koernig S, Silva A, Drane D, Maraskovsky E.

J Med Microbiol. 2012 Jul;61(Pt 7):935-43. doi: 10.1099/jmm.0.040857-0. Epub 2012 Mar 22. Review.


ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway.

Wilson NS, Yang B, Morelli AB, Koernig S, Yang A, Loeser S, Airey D, Provan L, Hass P, Braley H, Couto S, Drane D, Boyle J, Belz GT, Ashkenazi A, Maraskovsky E.

Immunol Cell Biol. 2012 May;90(5):540-52. doi: 10.1038/icb.2011.71. Epub 2011 Sep 6.


Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™.

Nicholaou T, Chen W, Davis ID, Jackson HM, Dimopoulos N, Barrow C, Browning J, Macgregor D, Williams D, Hopkins W, Maraskovsky E, Venhaus R, Pan L, Hoffman EW, Old LJ, Cebon J.

Cancer Immunol Immunother. 2011 Nov;60(11):1625-37. doi: 10.1007/s00262-011-1041-3. Epub 2011 Jun 23.


ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.


An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.

Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, Maraskovsky E, Endres S, Schnurr M.

Int J Cancer. 2011 Feb 15;128(4):897-907. doi: 10.1002/ijc.25399.


Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.

Robson NC, McAlpine T, Knights AJ, Schnurr M, Shin A, Chen W, Maraskovsky E, Cebon J.

Blood. 2010 Jul 15;116(2):218-25. doi: 10.1182/blood-2009-10-249458. Epub 2010 Apr 29.


Presentation of tumour antigens by dendritic cells and challenges faced.

Robson NC, Hoves S, Maraskovsky E, Schnurr M.

Curr Opin Immunol. 2010 Feb;22(1):137-44. doi: 10.1016/j.coi.2010.01.002. Epub 2010 Jan 29.


The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses.

Lahoud MH, Proietto AI, Ahmet F, Kitsoulis S, Eidsmo L, Wu L, Sathe P, Pietersz S, Chang HW, Walker ID, Maraskovsky E, Braley H, Lew AM, Wright MD, Heath WR, Shortman K, Caminschi I.

J Immunol. 2009 Jun 15;182(12):7587-94. doi: 10.4049/jimmunol.0900464.


Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant.

Maraskovsky E, Schnurr M, Wilson NS, Robson NC, Boyle J, Drane D.

Immunol Cell Biol. 2009 Jul;87(5):371-6. doi: 10.1038/icb.2009.21. Epub 2009 Apr 21. Review.


Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.

Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J.

Clin Cancer Res. 2009 Mar 15;15(6):2166-73. doi: 10.1158/1078-0432.CCR-08-2484. Epub 2009 Mar 10.


Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers.

Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, Shaw D, Gervase B, Coates S, Houghton M, Basser R.

Hum Vaccin. 2009 Mar;5(3):151-7. Epub 2009 Mar 15.


ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

Schnurr M, Orban M, Robson NC, Shin A, Braley H, Airey D, Cebon J, Maraskovsky E, Endres S.

J Immunol. 2009 Feb 1;182(3):1253-9. Erratum in: J Immunol. 2009 Apr 15;182(8):5152.


Activin-A attenuates several human natural killer cell functions.

Robson NC, Wei H, McAlpine T, Kirkpatrick N, Cebon J, Maraskovsky E.

Blood. 2009 Apr 2;113(14):3218-25. doi: 10.1182/blood-2008-07-166926. Epub 2009 Jan 13.


The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement.

Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin Teh J, Lo JC, Rizzitelli A, Wu L, Vremec D, van Dommelen SL, Campbell IK, Maraskovsky E, Braley H, Davey GM, Mottram P, van de Velde N, Jensen K, Lew AM, Wright MD, Heath WR, Shortman K, Lahoud MH.

Blood. 2008 Oct 15;112(8):3264-73. doi: 10.1182/blood-2008-05-155176. Epub 2008 Jul 30.


Cancer vaccines for established cancer: how to make them better?

Andrews DM, Maraskovsky E, Smyth MJ.

Immunol Rev. 2008 Apr;222:242-55. doi: 10.1111/j.1600-065X.2008.00612.x. Review.


Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production.

Robson NC, Phillips DJ, McAlpine T, Shin A, Svobodova S, Toy T, Pillay V, Kirkpatrick N, Zanker D, Wilson K, Helling I, Wei H, Chen W, Cebon J, Maraskovsky E.

Blood. 2008 Mar 1;111(5):2733-43. Epub 2007 Dec 21.


Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling.

Wilson NS, Young LJ, Kupresanin F, Naik SH, Vremec D, Heath WR, Akira S, Shortman K, Boyle J, Maraskovsky E, Belz GT, Villadangos JA.

Immunol Cell Biol. 2008 Feb;86(2):200-5. Epub 2007 Nov 20.


P2Y receptor signaling regulates phenotype and IFN-alpha secretion of human plasmacytoid dendritic cells.

Shin A, Toy T, Rothenfusser S, Robson N, Vorac J, Dauer M, Stuplich M, Endres S, Cebon J, Maraskovsky E, Schnurr M.

Blood. 2008 Mar 15;111(6):3062-9. Epub 2007 Nov 9.


ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.

Drane D, Gittleson C, Boyle J, Maraskovsky E.

Expert Rev Vaccines. 2007 Oct;6(5):761-72. Review.


GSK-3 mediates differentiation and activation of proinflammatory dendritic cells.

Rodionova E, Conzelmann M, Maraskovsky E, Hess M, Kirsch M, Giese T, Ho AD, Zöller M, Dreger P, Luft T.

Blood. 2007 Feb 15;109(4):1584-92. Epub 2006 Oct 10.


Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.

Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J.

J Immunother. 2006 Sep-Oct;29(5):499-511.


The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture.

Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D, Davey G, Kupresanin F, Li M, Maraskovsky E, Belz GT, Carbone FR, Shortman K, Heath WR, Villadangos JA.

Proc Natl Acad Sci U S A. 2006 Jul 11;103(28):10729-34. Epub 2006 Jun 28.


Gene structure and transcript analysis of the human and mouse EGF-TM7 molecule, FIRE.

Caminschi I, Vandenabeele S, Sofi M, McKnight AJ, Ward N, Brodnicki TC, Toy T, Lahoud M, Maraskovsky E, Shortman K, Wright MD.

DNA Seq. 2006 Feb;17(1):8-14.


Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

Nicholaou T, Ebert L, Davis ID, Robson N, Klein O, Maraskovsky E, Chen W, Cebon J.

Immunol Cell Biol. 2006 Jun;84(3):303-17. Review.


Directed evolution for improved secretion of cancer-testis antigen NY-ESO-1 from yeast.

Piatesi A, Howland SW, Rakestraw JA, Renner C, Robson N, Cebon J, Maraskovsky E, Ritter G, Old L, Wittrup KD.

Protein Expr Purif. 2006 Aug;48(2):232-42. Epub 2006 Mar 2.


Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals.

Luft T, Rodionova E, Maraskovsky E, Kirsch M, Hess M, Buchholtz C, Goerner M, Schnurr M, Skoda R, Ho AD.

Blood. 2006 Jun 15;107(12):4763-9. Epub 2006 Mar 9.


Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions.

Murphy R, Green S, Ritter G, Cohen L, Ryan D, Woods W, Rubira M, Cebon J, Davis ID, Sjolander A, Kypridis A, Kalnins H, McNamara M, Moloney MB, Ackland J, Cartwright G, Rood J, Dumsday G, Healey K, Maher D, Maraskovsky E, Chen YT, Hoffman EW, Old LJ, Scott AM.

Prep Biochem Biotechnol. 2005;35(2):119-34.


Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination.

Chen Q, Jackson H, Shackleton M, Parente P, Hopkins W, Sturrock S, MacGregor D, Maraskovsky E, Tai TY, Dimopoulos N, Masterman KA, Luke T, Davis ID, Chen W, Cebon J.

Cancer Immun. 2005 Mar 9;5:5.


Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development.

O'Keeffe M, Brodnicki TC, Fancke B, Vremec D, Morahan G, Maraskovsky E, Steptoe R, Harrison LC, Shortman K.

Int Immunol. 2005 Mar;17(3):307-14. Epub 2005 Jan 31.


Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.

Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID, Villadangos J, Shortman K, Maraskovsky E, Cebon J.

Blood. 2005 Mar 15;105(6):2465-72. Epub 2004 Nov 16.

Supplemental Content

Loading ...
Support Center